Free Trial

Accelerate Diagnostics Q4 2023 Earnings Report

Accelerate Diagnostics logo
$1.04 -0.04 (-3.70%)
As of 04:00 PM Eastern

Accelerate Diagnostics EPS Results

Actual EPS
-$0.89
Consensus EPS
-$0.62
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$3.03 million
Expected Revenue
$3.80 million
Beat/Miss
Missed by -$770.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Accelerate Diagnostics Earnings Headlines

The real reason gold is soaring (and likely to continue)
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat